Skip to content Skip to footer
Subscribe Now

NEWS

Mosaic Therapeutics & Astex Pharmaceutical
Mosaic Therapeutics In-Licenses ASTX029 & ASTX295 from Astex Pharmaceuticals for Combination Therapy Development for Oncology
Shots: Mosaic has in-licensed ASTX029 & ASTX295 from Astex (Otsuka Pharmaceutical’s subsidiary) to develop combination therapies using these assets, with the 1st combination study expected to begin in 2026 As per the deal, Astex granted Mosaic exclusive rights to develop combination products for pts with limited therapy options, receiving a 19% equity stake upfront &…
April 24, 2025
Boehringer Ingelheim & Tessellate Bio
Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors
Shots: BI & Tessellate Bio have entered into a research collaboration & global license agreement to develop oral therapies for ALT-positive tumors As per the terms, Tessellate Bio will receive near term payments incl. an upfront license fee, research funding & technical milestones along with downstream success-based milestones, making it an aggregate of ~$573M (~€500M)…
April 23, 2025
Veravas
Veravas Launches VeraBIND Tau to Detect Alzheimer’s Disease & other Tauopathies
Shots: Veravas has launched VeraBIND Tau to detect both symptomatic & pre-symptomatic pts with Alzheimer's disease (AD) or other tau-related neurodegenerative disorders (tauopathies) In an analytical verification study, VeraBIND Tau showed 96% sensitivity, 90% specificity, & 92% agreement with tau PET imaging, detecting Alzheimer’s-related tau & offering VeraBIND Tau score, a semi-quantitative measure of pathologically…
April 23, 2025
Regeneron & Fujifilm
Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies
Shots: FUJIFILM Diosynth Biotechnologies & Regeneron have entered into a 10-year manufacturing supply agreement, under which FUJIFILM will provide US-based manufacturing services for Regeneron As per the deal, FUJIFILM will receive ~$3B to manufacture biopharmaceuticals for Regeneron at its Holly Springs, North Carolina facility, which will begin operations in late 2025 Holly Springs site is…
April 23, 2025
Rona Therapeutics
Rona Therapeutics Reports NMPA’s IND Acceptance of RN1871 for Hypertension
Shots: China’s NMPA has accepted IND application for RN1871 for hypertension, with Rona planning to advance it in P-I trial to assess its safety, PK, & preliminary efficacy in humans Preclinical studies have demonstrated AGT suppression & sustained blood pressure control, with reduced dosing frequency of RN1871 RN1871 is engineered to suppress AGT mRNA expression in the…
April 22, 2025
Load more